MK 0249

Drug Profile

MK 0249

Alternative Names: MK-0249

Latest Information Update: 28 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Neuropsychotherapeutics
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Obesity; Schizophrenia; Sleep apnoea syndrome

Most Recent Events

  • 01 Jun 2012 Pharmacodynamics data from a phase I trial in Sleep apnoea syndrome reported by Merck
  • 10 Dec 2009 Adverse events data from a clinical trial in healthy subjects presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
  • 12 Dec 2006 Discontinued - Phase-I for Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top